PMID- 20824296
OWN - NLM
STAT- MEDLINE
DCOM- 20110609
LR  - 20211020
IS  - 1437-7799 (Electronic)
IS  - 1342-1751 (Linking)
VI  - 15
IP  - 1
DP  - 2011 Feb
TI  - Elevated serum levels of interleukin-18 in patients with overt diabetic 
      nephropathy: effects of miglitol.
PG  - 58-63
LID - 10.1007/s10157-010-0343-7 [doi]
AB  - BACKGROUND: Interleukin-18 (IL-18), a pro-inflammatory cytokine, is a predictor 
      of cardiovascular and renal disease in diabetic patients. Postprandial 
      hyperglycemia is one of the important factors contributing to an increase in the 
      circulating pro-inflammatory cytokine levels. This study investigated the effect 
      of miglitol, an alpha-glucosidase inhibitor, on postprandial hyperglycemia and IL-18 
      levels in diabetic patients with nephropathy. METHODS: Fifteen Japanese diabetic 
      patients with persistent proteinuria and preserved renal function were recruited. 
      The patients received 50 mg miglitol thrice daily after the baseline examinations 
      and were followed up for 12 weeks. A meal tolerance test was performed on eight 
      patients at baseline and week 12. The fasting miglitol concentration was measured 
      in seven patients just before the meal tolerance test. RESULTS: There were no 
      changes in the body weight, blood pressure, liver and renal function, and 
      proteinuria from baseline to week 12. However, the levels of glycated hemoglobin 
      and interleukin 18 significantly decreased from baseline to week 12. During the 
      meal tolerance test, plasma glucose was significantly decreased 60 min after 
      treatment with miglitol, whereas the serum concentration of insulin was not 
      changed. Fasting and postprandial levels of IL-18 were significantly decreased 
      from baseline to week 12. Serum miglitol concentrations showed a significantly 
      negative correlation with eGFR (r = -0.82, p = 0.02). However, the serum miglitol 
      concentrations did not changed during the course of this study. CONCLUSION: 
      Miglitol improved postprandial hyperglycemia and reduced serum IL-18 levels in 
      patients with stage 3 diabetic nephropathy. Miglitol may therefore prevent 
      atherosclerotic diseases and diabetic micro-vascular complications through 
      decreasing glucose swings and/or the circulating IL-18 level.
FAU - Uzu, Takashi
AU  - Uzu T
AD  - Department of Medicine, Shiga University of Medical Science, Otsu, Shiga 
      520-2192, Japan. takuzu@belle.shiga-med.ac.jp
FAU - Yokoyama, Hiroki
AU  - Yokoyama H
FAU - Itoh, Hirofumi
AU  - Itoh H
FAU - Koya, Daisuke
AU  - Koya D
FAU - Nakagawa, Atsushi
AU  - Nakagawa A
FAU - Nishizawa, Makoto
AU  - Nishizawa M
FAU - Maegawa, Hiroshi
AU  - Maegawa H
FAU - Yokomaku, Yukiyo
AU  - Yokomaku Y
FAU - Araki, Shin-Ichi
AU  - Araki S
FAU - Abiko, Atsuko
AU  - Abiko A
FAU - Haneda, Masakazu
AU  - Haneda M
LA  - eng
PT  - Journal Article
DEP - 20100909
PL  - Japan
TA  - Clin Exp Nephrol
JT  - Clinical and experimental nephrology
JID - 9709923
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Interleukin-18)
RN  - 0V5436JAQW (miglitol)
RN  - 19130-96-2 (1-Deoxynojirimycin)
SB  - IM
MH  - 1-Deoxynojirimycin/*analogs & derivatives/therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/complications/drug therapy/immunology
MH  - Diabetic Nephropathies/*blood/*drug therapy/*immunology
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Humans
MH  - Hyperglycemia/blood/drug therapy/immunology
MH  - Hypoglycemic Agents/therapeutic use
MH  - Interleukin-18/*blood
MH  - Postprandial Period
EDAT- 2010/09/09 06:00
MHDA- 2011/06/10 06:00
CRDT- 2010/09/09 06:00
PHST- 2010/04/05 00:00 [received]
PHST- 2010/08/09 00:00 [accepted]
PHST- 2010/09/09 06:00 [entrez]
PHST- 2010/09/09 06:00 [pubmed]
PHST- 2011/06/10 06:00 [medline]
AID - 10.1007/s10157-010-0343-7 [doi]
PST - ppublish
SO  - Clin Exp Nephrol. 2011 Feb;15(1):58-63. doi: 10.1007/s10157-010-0343-7. Epub 2010 
      Sep 9.